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Abstract
Since it is unknown whether b-lactam antimicrobial agents can be used effectively against borderline oxacillin-resistant Staphylococcus
aureus (BORSA) with oxacillin MICs ‡4 mg/L, the in vitro bactericidal activity and pharmacodynamic effect of oxacillin against clinical
BORSA isolates was evaluated. Time-kill experiments with oxacillin were performed and the results compared with those obtained with
vancomycin, daptomycin and linezolid against BORSA with oxacillin MICs ‡4 mg/L and BORSA with oxacillin MICs £2 mg/L.
Furthermore, the effect of b-lactamase production and plasmid proﬁle analysis were taken into account to clarify responses to oxacillin.
Oxacillin killing activity was attenuated against BORSA compared with ATCC 29213 since the pharmacodynamic parameters revealed
that the potency of oxacillin was markedly reduced (c. ten-fold) against BORSA with oxacillin MICs ‡4 mg/L. pBORa53-like plasmid-
containing BORSA with oxacillin MICs £2 mg/L showed markedly more regrowth. In conclusion, oxacillin was non-effective in the
eradication of either (i) BORSA with oxacillin MICs ‡4 mg/L or (ii) b-lactamase-hyperproducing BORSA (MICs £2 mg/L). Further
investigation into b-lactam dosing strategies against different BORSA strains is warranted in order to avoid possible therapy failure.
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Introduction
In addition to methicillin-sensitive (MSSA) and -resistant
Staphylococcus aureus (MRSA), borderline oxacillin-resistant
S. aureus (BORSA) have been described. BORSA strains exhi-
bit oxacillin MIC values enclosing the European Committee
on Antimicrobial Susceptibility Testing oxacillin break-point
of >2 mg/L, since BORSA strains with oxacillin MICs below
or above the break-point have been described [1,2]. BORSA
strains lack the MRSA-speciﬁc mecA gene on the Staphylo-
coccal Cassette Chromosome mec (SCCmec), and, conse-
quently, do not produce the low-afﬁnity penicillin-binding
protein (PBP)2a or -2’. The borderline phenotype has been
attributed to (i) hyperproduction of blaZ-encoded penicillin-
ase; and/or (ii) production of an inducible, plasmid-mediated,
membrane-bound methicillinase [2–5]; and/or (iii) different
modiﬁcations in the PBP1, -2 and -4 genes, due to spontane-
ous amino acid substitutions in the transpeptidase domain
[2,6,7]. Unfortunately, a unique trait that differentiates
BORSA strains from susceptible or resistant S. aureus iso-
lates has not yet been identiﬁed.
Outbreaks of BORSA infections have been reported at an
estimated incidence of 5% [8,9]. Treatment of early experi-
mental endocarditis and in vitro data suggest efﬁcacy of b-lac-
tamase-resistant penicillins against BORSA strains with an
oxacillin MIC of 2 mg/L by enhancement of the dosage
[10,11]. Whether BORSA with higher oxacillin MICs (‡4 mg/
L) can be treated effectively with b-lactamase-resistant
penicillins is unknown.
Correction added on 19/03/2013 after initial online publica-
tion. A duplicate of this article was published under the DOI:
10.1111/j.1469-0691.2009.02956.x. This duplicate has now
been deleted and its DOI redirected to this version of the
article.
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The aim of the present study was to examine the antibac-
terial activity of oxacillin compared with vancomycin,
daptomycin and linezolid, against three mecA-negative
BORSA isolates, M002, M008 and M015, with oxacillin MICs
‡4 mg/L and, comparatively, two BORSA isolates, M007 and
VU94, with oxacillin MICs £2 mg/L, using time-kill analysis.
Materials and Methods
Bacterial strains
Staphylococcus aureus ATCC 29213 and VU94 were used as
the MSSA and BORSA reference strains, respectively [4,12].
BORSA M015, which was investigated in more detail, was a
clinical isolate from a patient admitted to the Maastricht Uni-
versity Medical Centre. Fourteen other BORSA isolates,
including M002, M007 and M008, were isolates from general
practice patients.
VU94 and M007 were BORSA with oxacillin MICs £2 mg/L
and M002, M008 and M015 were BORSA with oxacillin MICs
‡4 mg/L. The S. aureus protein A (spa) types were t3033,
t078, t127, t002 and t091, respectively, associated with mul-
tilocus sequence type clonal complexes (CC) 25, CC25, CC1,
CC5 and CC7. The remaining 11 strains were subjected only
to susceptibility testing, using the Phoenix system (Becton
Dickinson, Sparks, MD, USA) as well as a microdilution tech-
nique. All BORSA strains tested positive for the S. aureus-spe-
ciﬁc femA gene and negative for the MRSA-speciﬁc mecA gene
[13]. ATCC 29213 and 25923 served as positive and negative
b-lactamase-producing controls, respectively [14,15].
Antibiotics
Daptomycin and linezolid were kindly supplied by the manu-
facturers (Novartis, Basel, Switzerland and Pﬁzer, Groton,
CT, USA, respectively). Oxacillin and vancomycin were pur-
chased (Sigma-Aldrich, Zwijndrecht, the Netherlands). Prior
to each experiment stock solutions were prepared.
Susceptibility testing
Susceptibility testing was performed using microdilution tech-
niques according to CLSI guidelines [16]. Daptomycin MICs
were determined using E-test strips (AB Biodisk, Solna, Swe-
den). Additionally, oxacillin MICs were determined using the
Phoenix system. Tolerance was deﬁned as a minimal bacteri-
cidal concentration (MBC)/MIC ratio ‡32 [17].
Time-kill experiments
Time-kill studies were done according to Isenberg’s
guidelines [18] and performed in Brain Heart Infusion (BHI)
broth (Oxoid, Basingstoke, UK). When testing daptomycin,
Mueller-Hinton broth II (BBL, Becton Dickinson, Le pont de
Claix, France) was supplemented with calcium (50 mg/L)
[19]. Bacteria from an overnight culture were grown until
late logarithmic phase and diluted to 1 · 106 CFU/mL. Anti-
biotics were added (100 lL per 10 mL medium) to obtain
concentrations of 0.5, 1, 2, 4 and 8 · MIC. Samples were
taken at t = 0, 2, 4, 6, 8, 10, 24 and 48 h of incubation at
37C, serially diluted (10)1 to 10)6) to minimize carryover
effects, plated (37.3 lL) using a spiralplater (Eddy Jet; IUL
Instruments, Barcelona, Spain) and incubated at 37C for
18–24 h. CFU were counted with a colony counter (Flash &
Go; IUL Instruments). The lower limit of detection was 2.73
log10 CFU/mL. Experiments with M015 and ATCC 29213
were repeated two- to eight-fold to test reproducibility.
Bactericidal activity (99.9% kill) was deﬁned as a ‡3-
log10 CFU/mL decrease in colony count at 24 h compared
with the initial inoculum.
Isolation and restriction of plasmid DNA
To analyse the presence of b-lactamase-encoding plasmids,
such as pBORa53, plasmid DNA was isolated and digested
with HindIII, essentially as described previously [20].
b-lactamase quantiﬁcation
Crude b-lactamase was prepared as described previously
[21]. Oxacillin was used as the inducer at a concentration of
0.375 mg/L. Uninduced cultures were also included. ATCC
29213 and 25923 were induced with 0.125 and 0.0625 mg/L
oxacillin (0.5 · MIC), respectively. The speciﬁc activity was
calculated by dividing the total activity by the protein content.
Statistical analysis
Differences between concentration proﬁles in log10 CFU/mL
at 24 h were assessed by analysis of variance with Tukey’s
test for multiple comparisons, using SPSS 14.0 software (SPSS
Inc., Chicago, IL, USA). A p-value of <0.05 was considered
statistically signiﬁcant.
Determination of pharmacodynamic parameters
An uncomplicated max-model can describe the change in
CFU over time during the initial phase of cell killing, using
the growth rate constant (k) in the absence of antibiotic
pressure and on the concentration-dependant kill rate
constant (), as shown in Equation 1.
dN
dt
¼ k emaxC
c
eCc50 þ Cc
 
 N: ð1Þ
The maximum kill rate constants max (h
)1) and concen-
tration necessary to achieve half of the maximum kill rate
C50 (mg/L) were obtained as described previously [22].
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However, this model can be inaccurate in estimating phar-
macodynamic parameters since effect–time proﬁles are often
not log-linear over a longer period of time. In order to
cover the overall effect over 24 h, the log difference viable
count was used as the difference between growth in the
presence and absence of an antibiotic. For each concentra-
tion, the effect (E) was deﬁned as the area under the curve
(AUC0–24) of the log difference curves (Equation 2), equal to
the area between the curves (ABC0–24), and calculated via
the trapezoidal rule method in Prism 4.0 (GraphPad Inc).
AUC Log10 CFUgrowthcontrol
  Log10 CFUantibioticð Þ 024 ð2Þ
The maximum effect (Emax) was determined by ﬁtting the
data to the Hill equation. To carry out a parallel line assay
[23], the logarithms of E/Emax)E were plotted against the
logarithm of the concentration (mg/L) according to the Hill
plot (Equation 3) [24].
Log E= Emax  Eð Þ½  ¼ cLog C½  þ K ð3Þ
The EC50 represents the concentration at which 50% of the
maximum effect is obtained and is therefore considered as a
potency marker. The EC50 is equal to 10
)K/c.
Results
Susceptibility testing
Similar MICs of daptomycin and vancomycin were observed
for BORSA with an MIC of oxacillin ‡4 mg/L (M002, M008
and M015) or £2 mg/L (M007 and VU94) (Table 1). Toler-
ance to oxacillin was noted for M002 and M008 [17]. Persist-
ers were observed when determining the MBC for M015
[25]. All BORSA, including eight isolates with oxacillin MICs
of 4 and 8 mg/L, tested on the Phoenix system, were
classiﬁed as susceptible to oxacillin (as shown for ﬁve strains
in Table 1).
Time-kill experiments
ATCC 29213 and all BORSA showed similar growth charac-
teristics; there were no considerable differences in the
effects of vancomycin, linezolid and daptomycin (Fig. 1,
Table 1). The EC50 and C50 values were of the same order,
except for vancomycin. Regrowth was especially observed
with vancomycin, even at 2 · MIC for all strains.
Oxacillin was signiﬁcantly less effective at 4 and
8 · MIC against M015, compared with ATCC 29213, in
TABLE 1. In vitro activity and pharmacodynamic parameters of oxacillin, vancomycin, daptomycin and linezolid against
BORSA
Bacterial
strains and
antibioticsa
MIC
(mg/L)
MICb
(mg/L)
MBC
(mg/L)
Time to 99.9% kill (h) Emax c
EC50
(mg/L)
c¢c
max,o/i
d
(h)1)
C50
(mg/L) c
2 · MIC 4 · MIC 8 · MIC Ie II e
29213 OXA 0.25 ND 0.5 21.36 18.31 15.09 121.03 2.28 0.20
2.20
0.94/2.00 0.19 1.66
M015 OXA 4 2 8f 26.61 27.38 25.59 95.88 1.85 2.01 0.52/1.50 2.22 2.59
M008 OXA 4 0.5 >64 44.32 47.96 44.30 80.22 2.29 1.89 0.75/1.93 1.58 2.05
M002 OXA 8 2 >64 NA NA NA 89.04 1.57 1.92 0.74/1.88 1.89 2.60
VU94 OXA 0.75 0.5 1 NA NA NA 100.40 1.67 0.42 1.06/2.05 0.31 2.03
M007 OXA 2 0.5 4 NA NA 18.89 75.02 2.07 0.61 0.75/1.67 0.49 2.94
29213 DAP 1 ND ND 4.92 3.63 2.10 176.52 0.85 0.66
1.05
2.05/2.82 0.57 0.88
M015 DAP 0.5 ND ND 9.15 6.82 6.10 131.47 1.64 0.26 1.18/1.82 0.14 1.55
M008 DAP 0.5 ND ND 7.42 5.21 4.39 147.40 1.09 0.21 1.28/2.02 0.24 1.42
M002 DAP 0.75 ND ND 4.03 4.88 3.48 147.80 1.03 0.08 1.27/2.10 0.29 1.36
VU94 DAP 0.75 ND ND 5.76 5.73 5.39 147.90 1.40 0.33 1.39/2.09 0.49 1.47
M007 DAP 0.75 ND ND 5.61 5.12 4.64 142.80 1.79 0.41 1.04/1.89 0.28 1.40
29213 LZD 4 ND ND NA NA NA 82.54 5.36 1.79
2.16
0.53/1.59 1.32 3.27
M015 LZD 1 ND ND NA 32.49 27.63 99.68 1.98 0.73 0.71/1.69 0.80 1.02
29213 VAN 1 ND ND NA 24.36 24.24 98.82 4.31 1.48
4.13
0.66/1.72 0.57 6.51
M015 VAN 1 ND ND NA 22.01 22.20 100.07 3.58 1.60 0.56/1.54 0.62 5.82
M008 VAN 1 ND ND NA 22.52 29.18 97.45 4.37 1.37 0.83/2.01 0.95 6.58
M002 VAN 1 ND ND NA 17.24 16.12 114.80 3.98 1.28 1.01/2.16 0.87 3.04
VU94 VAN 1 ND ND NA 21.97 20.00 102.20 2.83 1.34 0.84/1.84 0.63 5.85
M007 VAN 1 ND ND NA 20.85 17.24 103.90 4.14 1.83 0.77/1.69 1.27 3.92
ND, not determined; NA, not achieved within 48 h.
aDAP, daptomycin; LZD, linezolid; OXA, oxacillin; VAN, vancomycin.
bMIC values determined with the Phoenix system.
cCommon sigmoidicity coefﬁcients for strains ATCC 29213 and BORSA M015 when concentration–effect lines were forced to be in parallel.
dObserved (o) and intrinsic (i) maximum kill rate constants (max,i = max,o + k); the generation times (gt = t/((log2)
)1 · log (Nt/N0)) and k = ln2/gt) were in BHI or CAMHB
(DAP): 0.70 and 0.90; 0.70 and 0.99; 0.65 and 1.08; 0.61 and 0.83; 0.75 and 0.81 and 0.58 and 0.93 (h) for, respectively, ATCC 29213, VU94, M015, M002, M007 and M008.
eMethod I, effect expressed as the ABC0–24; method II, effect expressed as the kill rate ().
fPersisters detected up to 64 mg/L.
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reducing the bacterial viable counts over 24 h (p <0.05
and p <0.001), as was the time to achieve 99.9% killing at
2, 4 and 8 · MIC (5–10 h increase) (Table 1). This was
consistent with the lower max. A 99.9% kill of M002,
M008 and M015 was not achieved within 24 h, not even
at 8 · MIC.
The maximum effect of oxacillin on all BORSA was
considerably reduced compared with ATCC 29213
(Fig. 1a). Furthermore, marked regrowth at 2 and
4 · MIC was observed with BORSA M007 and VU94
(oxacillin MICs £2 mg/L), while no regrowth was seen
with BORSA with oxacillin MICs ‡4 mg/L (M002, M008
and M015) (Fig. 2).
b-Lactamase activity and plasmid proﬁle analysis
b-Lactamase activity and plasmid proﬁle analysis were per-
formed to clarify the differences in regrowth, observed in
the presence of oxacillin, between BORSA M007 and VU94,
and BORSA M002, M008 and M015, at the same multiples of
the MIC. Although BORSA M015, M008 and M002, with oxa-
cillin MICs ‡4 mg/L, showed induction ratios twice as high as
BORSA M007 and VU94 with oxacillin MIC £2 mg/L, the
latter produced considerably higher amounts of b-lactamase
after induction (Fig. 3a). The four plasmid DNA fragments of
BORSA M007 and VU94 were similar in size to that of
plasmid pBORa53 (Fig. 3b), previously described as a
pBW15-like b-lactamase-encoding plasmid [26]. In the other
BORSA, pMW2-like, penicillinase-encoding plasmids were
identiﬁed [27].
Pharmacodynamic comparison
For each antibiotic a potency ratio was calculated between
ATCC 29213 and M015, using the parallel line assay [23].
The difference in potency is visualized by the horizontal shift
of the concentration–effect curve (Fig. 4). Oxacillin was
approximately ten times more potent against ATCC 29213
than against M015. The same result was found for the other
BORSA, M002 and M008 with oxacillin MICs ‡4 mg/L. These
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FIG. 1. The pharmacodynamic effect, expressed as the difference in log viable count over a time period of 24 h, and denoted by the area
between the curves (ABC0–24), vs. the concentration in mg/L for (a) oxacillin, (b) vancomycin and (c) daptomycin against borderline oxacillin-
resistant Staphylococcus aureus strains M002, M007, M008, M015 and VU94 and methicillin-sensitive Staphylococcus aureus ATCC 29213.
Time (h)
Lo
g 1
0 
CF
U
/m
L
Lo
g 1
0 
CF
U
/m
L
0
2
4
6
8
10
Time (h)
0 10 20 30 40 50 0 10 20 30 40 50
0
2
4
6
8
10
(b)(a)
FIG. 2. Antibacterial activity of oxacillin (OXA) against (a) Staphylococcus aureus ATCC 29213 (white symbols and dotted lines) vs. the average
data for borderline oxacillin-resistant S. aureus (BORSA) strains M002, M008 and M015 (MICs of OXA ‡4 mg/L) (black symbols and straight
lines) and (b) S. aureus ATCC 29213 (white symbols and dotted lines) vs. the average data for BORSA strains M007 and VU94 (MICs of OXA
£2 mg/L) (black symbols and straight lines) at concentrations corresponding to 0.5· (circles), 1· (triangles downwards), 2· (squares), 4· (dia-
monds) and 8· MIC (triangles upwards) in comparison with growth controls (hexagon). Error bars represent standard errors of the mean.
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strains showed similar concentration–effect proﬁles, resulting
in consistent EC50 values (Fig. 1a). On the other hand, the
potency of oxacillin against ATCC 29213 was estimated to
be two- and three-times higher than against VU94 and M007,
respectively.
Discussion
This study revealed that oxacillin was not effective to eradi-
cate, in vitro, either BORSA with MICs of oxacillin ‡4 mg/L, or
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BORSA with MICs of oxacillin £2 mg/L. Actual concentrations
of oxacillin required to eradicate in vitro BORSA with oxacillin
MICs ‡4 mg/L (M002, M008 and M015) were notably higher
than can be attained with normal dosing strategies, whereas
M007 and VU94 (MICs of oxacillin £2 mg/L) showed early re-
growth in the presence of oxacillin, possibly due to pBORa53-
like plasmid-related hyperproduction of b-lactamase(s).
The change in killing rate over time is a reﬂection of the
inﬂuence of (i) degradation of antibiotics, (ii) adaptation, and
(iii) heterogeneous subpopulations [28]. Consequently,
regrowth can occur. Furthermore, the growth rate is not
constant over time since the replication of microorganisms is
inﬂuenced by the amount of nutrients in the medium. There-
fore, an alternative method, which incorporates all available
time-kill data, was used to obtain concentration–effect
parameters. In contrast to the method of Tsuji et al. [29],
who used the log ratio based on the proportion between
growth or killing in the absence and presence of an antibi-
otic, our method is based on the absolute difference
between these characteristics.
Because the kill rates were obtained from the log linear
initial phase of the survival curve, max was affected only min-
imally by regrowth. In contrast, the reduced efﬁcacy as a
result of regrowth was manifested in Emax, since the variation
in the survival curve over a longer period of time was taken
into account. This might clarify the discrepancy between
EC50 and C50 values (Table 1). The vancomycin effect is
overestimated by the C50 value.
The decreased EC50 of oxacillin for BORSA with oxacillin
MICs ‡4 mg/L (M002, M008 and M015) is accompanied by a
reduction in Emax. Usually, target site alterations are reﬂected
by a reduced Emax. BORSA resistance mechanisms have been
related, among others, related to target site alterations such
as amino acid substitutions in PBP2, which might explain the
reduced Emax [2,6]. Up-regulation of b-lactamases could be
responsible for the increased EC50. However, the production
of b-lactamases by these strains was only slightly enhanced
after induction, compared with ATCC 29213 (Fig. 3a).
Although the data do not allow the establishment of a speciﬁc
mechanism, other resistance mechanisms that have not been
elucidated so far might be involved. On the other hand, VU94,
and particularly M007 (BORSA with an oxacillin MIC £2 mg/L,
which both belong to the predominant CC25 lineage [2]),
showed a considerably higher production of b-lactamases
after induction. This is in accordance with the plasmid proﬁle
analysis since pBW15-like plasmids, such as pBORa53, are
associated with inducible hyperproduction of b-lactamases.
These plasmids probably encode a methicillinase [15]. Two
b-lactamases have been detected in the membrane of VU94
previously, one of them being a methicillinase [4]. For this
reason, VU94 and M007 were probably able to hydrolyze
oxacillin very efﬁciently, with regrowth within 12 h as a conse-
quence, at 4· and 8· MIC, respectively. This indicates the
need for high dosing strategies of penicillinase-resistant
penicillins for b-lactamase-hyperproducing BORSA. Unfortu-
nately, oxacillin in combination with a b-lactamase inhibitor is
not commercially available.
Although oxacillin against BORSA with oxacillin MICs ‡
4 mg/L (M002, M008 and M015) reduced the bacterial
counts at 4· and 8· MIC, the actual concentrations, i.e.
16–32 mg/L, were high. Concentrations above 4· MIC are
considered clinically effective for time-dependent antibiotics,
such as oxacillin [28]. As for b-lactams, the pharmacody-
namic index that correlates best with clinical outcome is
the time (t) during which serum concentrations of the
unbound fraction exceed the MIC (t > MIC) and values of
40–50% or greater are considered necessary for effective
treatment of S. aureus infections [30]. Therefore, it is very
unlikely that for a drug with a high protein binding afﬁnity
(94%) and an unfavourable EC50, a free plasma concentra-
tion of ‡4–8 mg/L (corresponding to the MIC for M002,
M008 and M015) for approximately 50% of the dosing inter-
val (t > MIC) can be attained with current dosage strategies
(IV, 1–12 g/24 h).
A recent case report has highlighted the fact that patients
infected with non-b-lactamase-producing BORSA, with oxa-
cillin MICs ‡4 mg/L, and treated with b-lactams may lead to
treatment failure [31]. The case report describes a patient
with endocarditis, due to BORSA with an oxacillin MIC
‡4 mg/L, who failed to respond to cloxacillin. This conﬁrms
our ﬁndings that treatment of infections caused by such
BORSA with b-lactams is full of risk.
Since this study showed that BORSA with oxacillin MICs
‡4 mg/L are difﬁcult to eradicate in vitro with b-lactam anti-
biotics, it is important to identify BORSA isolates by routine
susceptibility testing. However, 16 BORSA isolates, including
eight with oxacillin MICs of 4 and 8 mg/L, tested with the
Phoenix system, were all considered MSSA. Apparently, this
method is not suitable for differentiating between fully
susceptible S. aureus strains and BORSA. BORSA isolates will
thus be missed by routine susceptibility testing and, as a
consequence, the (empiric) antibiotic therapy choice, i.e.
oxacillin, is not useful for eradication.
In summary, out of the four antibiotics tested, oxacillin
was, in vitro, not effective against either BORSA with oxacillin
MICs ‡4 mg/L or pBORa53-like plasmid-containing BORSA
with oxacillin MICs £2 mg/L. Further investigation into
b-lactam dosing strategies against different BORSA strains is
warranted in order to avoid treatment options that are
adequate for MRSA infections.
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